Pulmonary artery intimal sarcoma misdiagnosed as pulmonary embolism: MDM2 amplification as the diagnostic anchor in an unresectable tumor—a case report

Abstract Background Pulmonary artery intimal sarcoma (PAIS) is a rare and aggressive vascular malignancy whose clinical and radiological features overlap with those of pulmonary thromboembolism (PTE); most patients are initially anticoagulated, and no standard systemic therapy exists for unresectable disease. Amplification of MDM2 is the defining genomic event, yet it is usually treated as a supplementary finding rather than as a diagnostic test. Case presentation A 51-year-old man without thromboembolic risk factors presented with cough, sputum production, and chest discomfort. Contrast-enhanced computed tomography (CT) showed filling defects extending from the main pulmonary artery into both branches together with a 5.0 × 2.7 cm left upper lobe mass, and he received rivaroxaban until hemoptysis occurred. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT showed concordant hypermetabolism of the intravascular and parenchymal lesions. Two biopsies, including an expert review, narrowed the differential only to intimal sarcoma versus sarcomatoid carcinoma; next-generation sequencing then identified MDM2 amplification with CDKN2A deletion, a low tumor mutational burden (1.95 mutations/Mb), and negative PD-L1 expression, establishing MDM2-driven PAIS. Because the tumor was unresectable, he received six cycles of sintilimab, docetaxel, and cisplatin, two further cycles of sintilimab and docetaxel, consolidative intensity-modulated radiotherapy (60 Gy in 25 fractions), and maintenance sintilimab monotherapy. The best response was stable disease with a 27.9% reduction in the sum of target-lesion diameters, and progression-free survival reached 12.1 months without grade ≥3 immune-related adverse events. Conclusions When morphology and immunohistochemistry are indeterminate, MDM2 amplification can be the decisive diagnostic test rather than a supplementary finding, and it should be sought before empirical treatment is committed. Chemotherapy-primed PD-1 blockade followed by consolidative radiotherapy produced durable disease control in an immunologically cold tumor; prospective registries are needed to test this sequence.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11465967/v1
Primary Topic
Sarcoma Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pulmonary artery intimal sarcoma misdiagnosed as pulmonary embolism: MDM2 amplification as the diagnostic anchor in an unresectable tumor—a case report

Hongmei Mou, Xu Xi, Yajie Zhu, Xiaorong Liu et al.
Research Square
Sarcoma Diagnosis and Treatment
preprint

Pulmonary artery intimal sarcoma misdiagnosed as pulmonary embolism: MDM2 amplification as the diagnostic anchor in an unresectable tumor—a case report

Hongmei Mou, Xu Xi, Yajie Zhu, Xiaorong Liu, You Wang, Yi Wang
preprint en

Abstract

Abstract Background Pulmonary artery intimal sarcoma (PAIS) is a rare and aggressive vascular malignancy whose clinical and radiological features overlap with those of pulmonary thromboembolism (PTE); most patients are initially anticoagulated, and no standard systemic therapy exists for unresectable disease. Amplification of MDM2 is the defining genomic event, yet it is usually treated as a supplementary finding rather than as a diagnostic test. Case presentation A 51-year-old man without thromboembolic risk factors presented with cough, sputum production, and chest discomfort. Contrast-enhanced computed tomography (CT) showed filling defects extending from the main pulmonary artery into both branches together with a 5.0 × 2.7 cm left upper lobe mass, and he received rivaroxaban until hemoptysis occurred. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT showed concordant hypermetabolism of the intravascular and parenchymal lesions. Two biopsies, including an expert review, narrowed the differential only to intimal sarcoma versus sarcomatoid carcinoma; next-generation sequencing then identified MDM2 amplification with CDKN2A deletion, a low tumor mutational burden (1.95 mutations/Mb), and negative PD-L1 expression, establishing MDM2-driven PAIS. Because the tumor was unresectable, he received six cycles of sintilimab, docetaxel, and cisplatin, two further cycles of sintilimab and docetaxel, consolidative intensity-modulated radiotherapy (60 Gy in 25 fractions), and maintenance sintilimab monotherapy. The best response was stable disease with a 27.9% reduction in the sum of target-lesion diameters, and progression-free survival reached 12.1 months without grade ≥3 immune-related adverse events. Conclusions When morphology and immunohistochemistry are indeterminate, MDM2 amplification can be the decisive diagnostic test rather than a supplementary finding, and it should be sought before empirical treatment is committed. Chemotherapy-primed PD-1 blockade followed by consolidative radiotherapy produced durable disease control in an immunologically cold tumor; prospective registries are needed to test this sequence.

Research Square
University of Electronic Science and Technology of China (CN), Sichuan Cancer Hospital (CN), Chengdu University of Traditional Chinese Medicine (CN)
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon